News

Patients with idiopathic pulmonary fibrosis (IPF) who demonstrate adequate lung volume still have the same rate of lung volume decline as patients with initially lower volumes, and benefit equally from treatment with Ofev (nintedanib), researchers reported. The study, “Nintedanib in patients with idiopathic pulmonary fibrosis and preserved…

Allakos recently presented preclinical data demonstrating the potential of its Siglec-8 antibodies in inhibiting components involved in fibrosis in rodent models of lung and skin fibrosis.  The company believes these antibodies could potentially benefit a wide spectrum of patients with conditions where fibrosis is a major contributor to the…

Building on previous research, scientists at Brown University report that a trio of proteins work together to promote a variety of lung diseases, including idiopathic pulmonary fibrosis (IPF). The findings, published by investigators led by Jack Elias in the journal Nature Communications, appeared in the article “IL-13Rα2 Uses TMEM219 In…

Global Blood Therapeutics (GBT) recently published positive preclinical results supporting the development of GBT440 for the treatment of lung diseases associated with hypoxemia (abnormally low levels of oxygen in the blood), such as idiopathic pulmonary fibrosis (IPF). The results were detailed in the study, “Increased hemoglobin–oxygen affinity ameliorates bleomycin‐induced hypoxemia…

Researchers used stem cells from patients with idiopathic pulmonary fibrosis (IPF) to create a lung “organoid” — a three-dimensional structure similar to the human lung — that stands to improve studies into lung diseases like IPF and research into personalized drug therapies, by allowing such investigations to take place in an environment…

Researchers suggest that a certain type of the immune system cell – called myeloid-derived suppressor cells (MDSC) – can serve as a biomarker to diagnose idiopathic pulmonary fibrosis (IPF). These cells may also distinguish stages of disease progression, as a greater loss of lung function was found in patients with higher levels of MDSCs in…

AdAlta, a biotech that develops protein-based therapeutics, has retained FujiFilm Diosynth Biotechnologies to manufacture AD-114, AdAlta’s lead drug molecule for the treatment of idiopathic pulmonary fibrosis (IPF). AdAlta is using its proprietary technology platform to create i-bodies, a new class of protein therapeutics that are the human equivalent of the antigen-binding domain…

Patara Pharma recently presented positive Phase 2 data on its lead candidate, PA101, for the treatment of refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The findings were given at the recent European Respiratory Society International Congress in London. PA101 is a late-stage immune modulator with mast…

The European Commission (EC) has granted Galapagos’ investigational product GLPG1690 orphan drug designation for the treatment of patients with idiopathic pulmonary fibrosis (IPF). GLPG1690 is a selective autotaxin inhibitor that was demonstrated to have a favorable safety and tolerability profile in a Phase 1 study in healthy volunteers. Autotaxin plays an…

Long-term treatment of idiopathic pulmonary fibrosis (IPF) patients with Ofev (nintedanib) showed positive effects in keeping disease progression at bay, while inducing manageable side effects, Boehringer Ingelheim Pharmaceuticals announced. This finding comes from the INPULSIS-ON clinical trial  — an extension study of the INPULSIS trial — designed to assess the long-term effects of…